JBM (Healthcare) Signs 2025 Europharm License Agreement

Reuters
10/28
JBM (Healthcare) Signs 2025 Europharm License Agreement

JBM (Healthcare) Ltd. has announced that Europharm and Europharm HK have entered into the 2025 Europharm License Agreement on 28 October 2025. Under this agreement, Europharm will grant a license to Europharm HK to use a portion of the Factory from 1 December 2025 to 27 January 2028, for a monthly license fee of HK$247,000. The agreement follows the expiration of the previous license on 30 November 2025. The directors of both Jacobson and JBM, including their independent non-executive directors, consider the terms of the agreement to be fair, reasonable, on normal commercial terms, and in the best interests of the companies and their shareholders. Certain directors abstained from voting on the relevant board resolutions to avoid potential conflicts of interest.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JBM (Healthcare) Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10